OCX
Oncocyte Corp
$2.59
Earnings Summary
Revenue | $0.31Mn |
Net Profits | $-15.99Mn |
Net Profit Margins | -5092.99% |
Highlights
Oncocyte Corp’s revenue jumped 14.6% since last year same period to $0.31Mn in the Q4 2023. On a quarterly growth basis, Oncocyte Corp has generated -26.81% fall in its revenue since last 3-months.
Oncocyte Corp’s net profit jumped 64.44% since last year same period to $-15.99Mn in the Q4 2023. On a quarterly growth basis, Oncocyte Corp has generated -146.45% fall in its net profits since last 3-months.
Oncocyte Corp’s net profit margin jumped 68.97% since last year same period to -5092.99% in the Q4 2023. On a quarterly growth basis, Oncocyte Corp has generated -236.71% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Oncocyte Corp post its latest quarter earnings
EPS Estimate Current Quarter | -0.76 |
EPS Estimate Current Year | -0.76 |
Highlights
Oncocyte Corp’s earning per share (EPS) estimates for the current quarter stand at -0.76 - a 33.33% jump from last quarter’s estimates.
Oncocyte Corp’s earning per share (EPS) estimates for the current year stand at -0.76.
Key Ratios
Key ratios of the Oncocyte Corp post its Q1 2024 earnings
Earning Per Share (EPS) | -2.12 |
Highlights
Oncocyte Corp’s earning per share (EPS) fell -10700% since last year same period to -2.12 in the Q1 2024. This indicates that the Oncocyte Corp has generated -10700% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-05-09 | -0.76 | -2.12 | -178.95% |
₹0 US Stocks a/c Opening Fee